Published • loading... • Updated
Argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
The all-cash deal adds Forte’s FB102, a first-in-class anti-CD122 antibody with Phase 1b data in vitiligo and celiac disease.
- On Monday, July 27, 2026, ARGX announced a definitive agreement to acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion.
- Following positive FB102 Phase 1b data in vitiligo and celiac disease reported by Forte Biosciences, the candidate emerged as a potential pipeline-in-a-product addressing multiple autoimmune conditions with high unmet need.
- ARGX's offer represents a premium of approximately 86% over Forte Biosciences' volume-weighted average price since the company reported positive vitiligo data on July 9, 2026.
- ARGX will host an investor conference call today at 8:00 a.m. to discuss the transaction, which requires no external financing and will be funded entirely from cash on hand.
- Expected to close in Q3 2026, the acquisition adds a differentiated approach to targeting pathogenic T-cell and NK-cell activity, broadening ARGX's ability to pursue immune-driven diseases.
Insights by Ground AI
17 Articles
17 Articles
Forte Biosciences agrees to $2.2 billion buyout
Dallas-based Forte Biosciences is getting acquired by a Dutch pharma giant for $2.2 billion, while Lincoln Property Co. has raised $400 million and a billionaire's family office has done another RIA deal. Get the latest M&A and funding news in North Texas in our latest deal wrap.
·Charlotte, United States
Read Full Article
Argenx announced that it has reached an agreement to purchase Forte Biosciences for $2.2 billion, in a movement to strengthen its immunology portfolio. Exclusive material for subscribers. To have full access, access the link of the subject and register.
·Rio de Janeiro, Brazil
Read Full Article
Coverage Details
Total News Sources17
Leaning Left0Leaning Right2Center9Last UpdatedBias Distribution82% Center
Bias Distribution
- 82% of the sources are Center
82% Center
C 82%
R 18%
Factuality
To view factuality data please Upgrade to Premium
